Loading company…
OneTar Biomedicine develops biopharmaceutical products and an organoid live bank platform.
OneTar Biomedicine develops biopharmaceutical products and therapeutics for health conditions. It is also industrializing an organoid live bank platform for pharmaceutical companies and research teams. Founded in 2020 and based in Shanghai, China, the company raised Series A funding in January 2026, led by GSR United Capital, with Winreal Investment and returning investor Hefei State-Owned Assets Holding.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in